Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 206

1.

Chemical castration and anti-androgens induce differential gene expression in prostate cancer.

Lehmusvaara S, Erkkilä T, Urbanucci A, Waltering K, Seppälä J, Larjo A, Tuominen VJ, Isola J, Kujala P, Lähdesmäki H, Kaipia A, Tammela TLj, Visakorpi T.

J Pathol. 2012 Jul;227(3):336-45. doi: 10.1002/path.4027. Epub 2012 May 8.

PMID:
22431170
2.

Goserelin and bicalutamide treatments alter the expression of microRNAs in the prostate.

Lehmusvaara S, Erkkilä T, Urbanucci A, Jalava S, Seppälä J, Kaipia A, Kujala P, Lähdesmäki H, Tammela TL, Visakorpi T.

Prostate. 2013 Jan;73(1):101-12. doi: 10.1002/pros.22545. Epub 2012 Jun 5.

PMID:
22674191
3.

Maximal androgen blockade for advanced prostate cancer.

Klotz L.

Best Pract Res Clin Endocrinol Metab. 2008 Apr;22(2):331-40. doi: 10.1016/j.beem.2008.01.004. Review.

PMID:
18471790
4.

Androgen deprivation therapy for volume reduction, lower urinary tract symptom relief and quality of life improvement in patients with prostate cancer: degarelix vs goserelin plus bicalutamide.

Axcrona K, Aaltomaa S, da Silva CM, Ozen H, Damber JE, Tankó LB, Colli E, Klarskov P.

BJU Int. 2012 Dec;110(11):1721-8. doi: 10.1111/j.1464-410X.2012.11107.x. Epub 2012 Apr 13.

5.

Effect of total androgen ablation on pathologic stage and resection limit status of prostate cancer. Initial results of the Italian PROSIT study.

Montironi R, Diamanti L, Santinelli A, Galetti-Prayer T, Zattoni F, Selvaggi FP, Pagano F, Bono AV.

Pathol Res Pract. 1999;195(4):201-8.

PMID:
10337657
6.

The long-term results with delayed-combined androgen blockade therapy in local or locally advanced prostate cancer.

Soga N, Hori Y, Ogura Y, Hayashi N, Sugimura Y.

Jpn J Clin Oncol. 2012 Jun;42(6):534-40. doi: 10.1093/jjco/hys037. Epub 2012 Mar 20.

PMID:
22438406
7.

[Intermittent androgen deprivation treatment of prostate cancer restarted at low level of serum prostate specific antigen: a pilot study].

Maekawa S, Maegawa M, Ushida H, Inoue K, Kaneko Y, Ohmori K, Nishimura K.

Hinyokika Kiyo. 2001 Aug;47(8):553-5. Japanese.

8.

[8-month neoadjuvant hormonal therapy before radical prostatectomy for high-risk prostate cancer].

Tabata K, Satoh T, Matsumoto K, Fujita T, Irie A, Iwamura M, Yanagisawa N, Matsuda D, Muramoto M, Kadowaki K, Suyama K, Shoji K, Koh H, Kawakami T, Okayasu I, Egawa S, Baba S.

Nihon Hinyokika Gakkai Zasshi. 2006 Jul;97(5):712-8. Japanese.

9.

Intermittent versus continuous androgen deprivation in prostate cancer.

Hussain M, Tangen CM, Berry DL, Higano CS, Crawford ED, Liu G, Wilding G, Prescott S, Kanaga Sundaram S, Small EJ, Dawson NA, Donnelly BJ, Venner PM, Vaishampayan UN, Schellhammer PF, Quinn DI, Raghavan D, Ely B, Moinpour CM, Vogelzang NJ, Thompson IM Jr.

N Engl J Med. 2013 Apr 4;368(14):1314-25. doi: 10.1056/NEJMoa1212299.

11.

Endocrine treatment of prostate cancer.

Tammela T.

J Steroid Biochem Mol Biol. 2004 Nov;92(4):287-95. Epub 2004 Dec 31. Review.

PMID:
15663992
12.

Undetectable level of prostate specific antigen (PSA) nadir predicts PSA biochemical failure in local prostate cancer with delayed-combined androgen blockade.

Soga N, Arima K, Sugimura Y.

Jpn J Clin Oncol. 2008 Sep;38(9):617-22. doi: 10.1093/jjco/hyn071. Epub 2008 Aug 12.

PMID:
18697759
13.

Androgen-deprivation therapy in men with metastatic prostate cancer: less may not necessarily be more.

Fui MN, Grossmann M.

Asian J Androl. 2013 Jul;15(4):445-6. doi: 10.1038/aja.2013.57. Epub 2013 May 20. No abstract available.

14.

Intermittent androgen deprivation therapy may prolong the duration of androgen dependence of well-differentiated prostate cancer.

Kaneko Y, Maekawa S, Arakaki R, Okada Y, Terada N, Nishimura K.

Hinyokika Kiyo. 2006 Apr;52(4):259-64.

15.

Targeted androgen pathway suppression in localized prostate cancer: a pilot study.

Mostaghel EA, Nelson PS, Lange P, Lin DW, Taplin ME, Balk S, Ellis W, Kantoff P, Marck B, Tamae D, Matsumoto AM, True LD, Vessella R, Penning T, Hunter Merrill R, Gulati R, Montgomery B.

J Clin Oncol. 2014 Jan 20;32(3):229-37. doi: 10.1200/JCO.2012.48.6431. Epub 2013 Dec 9.

16.

Re: Intermittent versus continuous androgen deprivation in prostate cancer.

Taneja SS.

J Urol. 2013 Dec;190(6):2093-4. doi: 10.1016/j.juro.2013.08.102. Epub 2013 Sep 7. No abstract available.

PMID:
24209518
17.

Androgen deprivation for prostatic carcinoma: a rationale for choosing components.

Fourcade RO, Chatelain C.

Int J Urol. 1998 Jul;5(4):303-11. Review.

18.

Current status of endocrine therapy for prostate cancer in Japan analysis of primary androgen deprivation therapy on the basis of data collected by J-CaP.

Hinotsu S, Akaza H, Usami M, Ogawa O, Kagawa S, Kitamura T, Tsukamoto T, Naito S, Namiki M, Hirao Y, Murai M, Yamanaka H; Japan Study Group of Prostate Cancer (J-CaP).

Jpn J Clin Oncol. 2007 Oct;37(10):775-81. Epub 2007 Oct 26.

PMID:
17965423
19.

Words of wisdom. Re: Intermittent versus continuous androgen deprivation in prostate cancer.

Sciarra A.

Eur Urol. 2013 Dec;64(6):1014-5. doi: 10.1016/j.eururo.2013.09.031. No abstract available.

PMID:
24209449
20.

Effects of bicalutamide and 4OH-tamoxifen on androgen-regulated gene expression in the LNCaP cell line.

Mangerini R, Argellati F, Pfeffer U, Boccardo F.

Anticancer Res. 2012 Dec;32(12):5323-9.

PMID:
23225433

Supplemental Content

Support Center